Ptc Therapeutics (PTCT) Cash from Operations (2012 - 2026)

Ptc Therapeutics' Cash from Operations history runs 15 years deep, the most recent figure standing at 129113000.0 for Q2 2026.

• In Q2 2026, Cash from Operations rose 321.34% year-over-year to 129113000.0; the TTM figure through Jun 2026 stood at 30503000.0 (down 104.33% YoY), while the FY2025 annual figure was 711196000.0, up 760.42% from the prior year.
• Cash from Operations for Q2 2026 stood at 129113000.0, up from 59042000.0 in the prior quarter.
• The five-year high for Cash from Operations was 870103000.0 in Q1 2025, with the low at 165963000.0 in Q4 2022.
• The 5-year median for Cash from Operations is 46643500.0 (2022), against an average of 8805944.44.
• The sharpest annual moves came in 2024 and 2025: Cash from Operations slumped 430.28% in 2024, then surged 1129.64% in 2025.
• Ptc Therapeutics' Cash from Operations stood at 165963000.0 in 2022, then surged by 39.57% to 100288000.0 in 2023, then jumped by 70.08% to 30004000.0 in 2024, then decreased by 14.23% to 34273000.0 in 2025, then soared by 476.72% to 129113000.0 in 2026.
• Business Quant data shows PTCT's Cash from Operations at 129113000.0 in Q2 2026, 59042000.0 in Q1 2026, and 34273000.0 in Q4 2025.